Alprostadil Injection Msds
Alprostadil Injection Msds
Alprostadil Injection Msds
2. HAZARDS IDENTIFICATION
Appearance: Signal Word: Statement of Hazard: Additional Hazard Information: Short Term: Clear liquid DANGER Highly flammable liquid and vapor.
Long Term:
May cause eye and skin irritation. May be harmful if absorbed through the skin. May be harmful if swallowed. Harmful if inhaled . Exposure to high concentrations may cause irritation, headache, drowsiness, and symptoms of alcohol intoxication. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system, the developing fetus. This product contains ethanol which can cause liver changes, central nervous system effects, and birth defects in the developing fetus Clinical use of this drug has caused symptoms of asthma, vomiting, diarrhea, increased bleeding time, clotting abnormalities, flushing, decrease in blood pressure (hypotension), decreased heart rate (bradycardia). Stimulates smooth muscle contraction. F - Highly flammable
EU Risk Phrases: Australian Hazard Classification (NOHSC): R11 - Highly flammable. Hazardous Substance. Dangerous Goods.
_______________________________________________________________________________________________________
2. HAZARDS IDENTIFICATION
Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
3. COMPOSITION/INFORMATION ON INGREDIENTS
Hazardous Ingredient Ethanol Alprostadil Additional Information: CAS Number 64-17-5 745-65-3 EU EINECS/ELINCS List 200-578-6 212-017-2 Classification F;R11 Xn;R22 % 99.95 0.05
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
For the full text of the R phrases mentioned in this Section, see Section 16
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
_______________________________________________________________________________________________________
Measures for Cleaning / Collecting: Measures for Environmental Protections: Additional Consideration for Large Spills:
Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly. Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release. Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
Storage Conditions:
1000 ppm TWA Listed 1000 ppm 1880 mg/m3 Listed Listed Listed Listed Listed Listed Listed Listed 500 ppm 960 mg/m3 500 ppm MAK 960 mg/m3 MAK Listed Listed Listed Listed Listed 1000 ppm 1900 mg/m3 Listed Listed Listed Listed Listed Listed
0.5 g/m3
_______________________________________________________________________________________________________
Flammablity: Flash Point (Liquid) (C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.):
Acute Toxicity: (Species, Route, End Point, Dose) Alprostadil Rat Oral LD 50 228 mg/kg Rat Intravenous LD 50 19.2 mg/kg Rat Intraperitoneal LD 50 24.9 mg/kg Mouse Oral LD 50 186 mg/kg _______________________________________________________________________________________________________ ALPROSTADIL INJECTION
_______________________________________________________________________________________________________
Rabbit
Severe
Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s)) Alprostadil Not specified
Rat
Oral 1 mg/kg/day
Genetic Toxicity: (Study Type, Cell Type/Organism, Result) Alprostadil Bacterial Mutagenicity (Ames) Unscheduled DNA Synthesis Mammalian Cell Mutagenicity Carcinogen Status: Ethanol IARC: NTP: OSHA:
Salmonella Negative Negative HGPRT Negative None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
Aquatic Toxicity: (Species, Method, End Point, Duration, Result) Ethanol Fingerling Trout NPDES LC50 24 Hours Rainbow Trout NPDES LC50 96 Hours Fathead minnow NPDES LC50 96 Hours
_______________________________________________________________________________________________________
_______________________________________________________________________________________________________
Canada - WHMIS: Classifications WHMIS hazard class: Class B, Division 2 Class D, Division 2, and Subdivision B.
Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List Alprostadil Standard for the Uniform Scheduling for Drugs and Poisons: EU EINECS/ELINCS List
carcinogen, initial date 7/1/88 (when associated with alcohol abuse) developmental toxicity, initial date 10/1/87 (when in alcoholic beverages) Listed Listed 200-578-6
Schedule 4 212-017-2
Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 14 Transport Information. Updated Section 15 - Regulatory Information. Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety Operations
Prepared by:
Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. End of Safety Data Sheet _______________________________________________________________________________________________________ ALPROSTADIL INJECTION
_______________________________________________________________________________________________________